Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

被引：0
|
作者：
G. S. Falchook
M. Duvic
D. S. Hong
J. Wheler
A. Naing
J. Lim
R. Kurzrock
机构：
[1] The University of Texas MD Anderson Cancer Center,Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program)
[2] The University of Texas MD Anderson Cancer Center,Unit 455
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Bortezomib; Gemcitabine; Liposomal doxorubicin; Cutaneous T-cell lymphoma; Small cell carcinoma; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1117 / 1126
页数：9
相关论文
共 50 条
  • [1] Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies
    Falchook, G. S.
    Duvic, M.
    Hong, D. S.
    Wheler, J.
    Naing, A.
    Lim, J.
    Kurzrock, R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1117 - 1126
  • [2] Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    Ryan, David P.
    Appleman, Leonard J.
    Lynch, Thomas
    Supko, Jeffrey G.
    Fidias, Panagiotis
    Clark, Jeffrey W.
    Fishman, Mayer
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kashala, Oscar
    Cusack, James, Jr.
    Eder, Joseph P.
    CANCER, 2006, 107 (10) : 2482 - 2489
  • [3] A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer
    Noelle K. LoConte
    James P. Thomas
    Dona Alberti
    Jennifer Heideman
    Kimberly Binger
    Rebecca Marnocha
    Kyle Utecht
    Peter Geiger
    Jens Eickhoff
    George Wilding
    Jill Kolesar
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 109 - 115
  • [4] A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer
    LoConte, Noelle K.
    Thomas, James P.
    Alberti, Dona
    Heideman, Jennifer
    Binger, Kimberly
    Marnocha, Rebecca
    Utecht, Kyle
    Geiger, Peter
    Eickhoff, Jens
    Wilding, George
    Kolesar, Jill
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 109 - 115
  • [5] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    Schelman, William R.
    Traynor, Anne M.
    Holen, Kyle D.
    Kolesar, Jill M.
    Attia, Steven
    Hoang, Tien
    Eickhoff, Jens
    Jiang, Zhisheng
    Alberti, Dona
    Marnocha, Rebecca
    Reid, Joel M.
    Ames, Matthew M.
    McGovern, Renee M.
    Espinoza-Delgado, Igor
    Wright, John J.
    Wilding, George
    Bailey, Howard H.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1539 - 1546
  • [6] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R. Schelman
    Anne M. Traynor
    Kyle D. Holen
    Jill M. Kolesar
    Steven Attia
    Tien Hoang
    Jens Eickhoff
    Zhisheng Jiang
    Dona Alberti
    Rebecca Marnocha
    Joel M. Reid
    Matthew M. Ames
    Renee M. McGovern
    Igor Espinoza-Delgado
    John J. Wright
    George Wilding
    Howard H. Bailey
    Investigational New Drugs, 2013, 31 : 1539 - 1546
  • [7] Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial
    Schmid, P
    Krocker, J
    Schulz, CO
    Michniewicz, K
    Dieing, A
    Eggemann, H
    Heilmann, V
    Blohmer, JU
    Sezer, O
    Elling, D
    Possinger, K
    ANTI-CANCER DRUGS, 2005, 16 (01) : 21 - 29
  • [8] A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    Dees, E. Claire
    O'Neil, Bert H.
    Lindley, Celeste M.
    Collichio, Frances
    Carey, Lisa A.
    Collins, Jason
    Riordan, William J.
    Ivanova, Anastasia
    Esseltine, Dixie
    Orlowski, Robert Z.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 99 - 107
  • [9] A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    E. Claire Dees
    Bert H. O’Neil
    Celeste M. Lindley
    Frances Collichio
    Lisa A. Carey
    Jason Collins
    William J. Riordan
    Anastasia Ivanova
    Dixie Esseltine
    Robert Z. Orlowski
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 99 - 107
  • [10] Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies
    Francois Goldwasser
    Sandrine Faivre
    Jerome Alexandre
    Cinthya Coronado
    Eva M. Fernández-García
    Carmen M. Kahatt
    Pilar García Paramio
    Jorge Luis Iglesias Dios
    Bernardo Miguel-Lillo
    Eric Raymond
    Investigational New Drugs, 2014, 32 : 500 - 509
12345